Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe
12:10pm, Monday, 30'th Aug 2021
Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
11:50am, Friday, 27'th Aug 2021
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The approval covers children from 2 years u
SAN RAFAEL, Calif.--(BUSINESS WIRE)--European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (voso
BioMarin: More Opportunities Ahead
04:26pm, Wednesday, 25'th Aug 2021
The value of the current BioMarin's business + Voxzogo is $104 per share.
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
08:30am, Wednesday, 25'th Aug 2021
SAN RAFAEL, Calif., Aug. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences.
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
06:19am, Friday, 20'th Aug 2021
All it will take is an FDA approval and a partial repeat of history.
BioMarin Is Highly Attractive For Longer-Term Investors
12:56pm, Wednesday, 18'th Aug 2021
BioMarin Is Highly Attractive For Longer-Term Investors
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
03:59pm, Thursday, 29'th Jul 2021
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
07:12am, Thursday, 29'th Jul 2021
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq p
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaimé on Q2 2021 Results - Earnings Call Transcript
10:23pm, Wednesday, 28'th Jul 2021
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaimé on Q2 2021 Results - Earnings Call Transcript
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
07:44pm, Wednesday, 28'th Jul 2021
BioMarin (BMRN) delivered earnings and revenue surprises of 76.67% and 11.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Bounces Back With Solid Results
07:14pm, Wednesday, 28'th Jul 2021
A strong quarterly sales report, and a new product approval, brighten the outlook for the maker of rare-disease treatments.
Biomarin Pharmaceutical: Q2 Earnings Insights
04:51pm, Wednesday, 28'th Jul 2021
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the past year to $0.07,
BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know
01:41pm, Wednesday, 28'th Jul 2021
BioMarin (BMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
